-
Caliper Life Sciences Reports First Quarter 2011 Results
Monday, May 2, 2011 - 7:05am | 92Caliper Life Sciences (NASDAQ: CALP) today reported its financial results for the first quarter of 2011. First quarter revenue increased to $35.8 million, or 25%, from $28.7 million in the same period of 2010. This increase was principally driven by year-over-year 26% organic growth of comparable...
-
TOP 15 Stocks To Watch this week- AAPL, BRK-A, BRK-B, BJ, C, F, GM, GPRO, IP, KND, N, NRTLQ, ONTY, SPPI, YRCW
Monday, May 2, 2011 - 4:48am | 2069Ford (NYSE:F)- Ford revenue increased 17% from last year to $33.1 billion and reduced its debt by $2.5 billion. The result showed an increase of $466 million over the first quarter of 2010, and is the best first quarter earnings since 1998. Competitors- General Motors Company (GM), Toyota Motor...
-
UBS Research Summary (FLEX, ARW, BHI, BKI, CTXS, DPS, EGN, ESRX, ISIL, LIS, PH, TMO, UHS, WLP, XLNX, NSC)
Thursday, April 28, 2011 - 12:25pm | 250In today's UBS research summary, UBS lowered the price target of Flextronics International (NASDAQ: FLEX) from $10 to $9.50. UBS increased the price targets of Arrow Electronics (NYSE: ARW) from $47 to $52, Baker Hughes (NYSE: BHI) from $87 to $95, Buckeye Technologies (NYSE: BKI) from $28 to $29...
-
UPDATE: Jefferies Raises PT on Thermo Fisher Scientific to $68 (TMO)
Thursday, April 28, 2011 - 9:29am | 90Jefferies is out with its report today on Thermo Fisher Scientific (NYSE: TMO), raising its PT from $66 to $68. In a note to clients, Jefferies writes, "TMO's 1Q11 EPS of $0.92 was $0.04 ahead of consensus on stronger revenue growth and better profit trends. We are raising our 2011 EPS forecast to...
-
Top five companies Stocks in the Specialty Chemicals industry- ROC, NLC, CYT, FOE, ECL
Thursday, April 28, 2011 - 9:14am | 12001) Rockwood Holdings (NYSE:ROC) ranks first with a gain of 10.09%- The company reported net income of $178 million, or $2.24 a share, for the three months ended March 31. That compares with net income of $36.9 million, or 48 cents a share, in the same quarter last year. The results included a $...
-
Stocks we are watching on 4/28- AMZN, LVLT, NFLX, BIDU, ORCL, YRCW, AMD, GS, POT, FCX, SNDK, IRE, AIB, CIGX, CTIC, AKAM, WFMI
Thursday, April 28, 2011 - 9:09am | 1328Amazon.com Inc. (AMZN) - Amazon.com Inc. (AMZN) broke out above $190 on Wednesday. AMZN will have resistance at $200. Pullbacks below $175 are a buy. Level 3 Communications Inc. (LVLT) - Level 3 Communications Inc. (LVLT) is back above $1.60. Level 3 Communications will have resistance at $1.85....
-
Bruker Corporation Reports EPS of $0.14 vs. $0.15 Estimate; Revenues $357M vs. $339.66M Estimate (BRKR)
Thursday, April 28, 2011 - 8:41am | 22Bruker Corporation (NASDAQ: BRKR) Reports EPS of $0.14 vs. $0.15 Estimate; Revenues $357M vs. $339.66M Estimate
-
Deutsche Bank Maintains PT, Rating On NKTR After In-Line Results
Thursday, April 28, 2011 - 8:15am | 90Deutsche Bank is maintaining its Buy rating and its $14 price target on Nektar Therapeutics (NASDAQ: NKTR) based upon the company's in-line Q1 results. According to Deutsche Bank, “With a steadily growing royalty stream from 9 products, 6 programs in late-stage development (1 proprietary, 5...
-
NKTR Revenue And EPS Below Consensus But "Neither Truly Matter At This Point," Says Brean Murray
Thursday, April 28, 2011 - 8:14am | 46Nektar Therapeutics (NASDAQ: NKTR) reported 1Q11 revenue of $11.3 million and EPS of $(0.33), “both of which are below consensus of $17.2 and $(0.27), but neither truly matter at this point in Nektar's development,” Brean Murray reports. Nektar Therapeutics closed Wednesday at $9.96.
-
Oppenheimer Reviews Affymetrix 1Q Results
Thursday, April 28, 2011 - 7:11am | 100In a recent report by Oppenheimer, it gave a quarterly update for Affymetrix Inc. (NASDAQ: AFFX) following the release of AFFX's 1Q earnings. According to Oppenheimer, Affymetrix experienced negative revenue growth but were close to forecast expectations. Oppenheimer explains, “1Q11 revenue of $73...
-
In-Depth Look At Genetic Technologies And Its Skyrocketing Share Price (GENE)
Wednesday, April 27, 2011 - 2:13pm | 273Genetic Technologies Limited (NASDAQ: GENE), the first Australian CLIA approved laboratory, had its stock nearly double in price today on news of a newly approved breast cancer test. Genetic Technologies has gained certification of its Australian laboratory under the US Clinical Laboratories...
-
Negative Rumors About SEQUENOM Circulate (SQNM)
Wednesday, April 27, 2011 - 1:13pm | 101Unconfirmed Negative rumors circulating at SEQUENOM (NASDAQ: SQNM). Hearing $2 Price Target https://intranet.pacificgrowth.com/clientsite/Research/clientReport.asp?Path=/P-S/SQNM/SQNM_2011_4%2027_QUICK_1Q11%20Review.pdf This article may include mentions of rumors, chatter, or unconfirmed...
-
Piper Jaffray Comments On Illumina Following Solid Quarterly Results
Wednesday, April 27, 2011 - 10:01am | 182Illumina (NASDAQ: ILMN) reported solid 1Q11 results, easily beating both Piper Jaffray's and Street consensus revenue and EPS expectations. Consistent with the latest database update, sequencing continues to gain traction, with strong HiSeq 2000 instrument demand and sequencing consumable strength...
-
Morning Market Movers (GENE, RLOC, CLUB, SIMG)
Wednesday, April 27, 2011 - 9:47am | 119Genetic Technologies Ltd (NASDAQ: GENE) surged 67.20% to $5.30 at 9:45 am. GENE received approval for the US launch of the BREVAGen breast cancer test. ReachLocal Inc (NASDAQ: RLOC) shares advanced 21.68% to $21.89. RLOC reported a 76% year-over-year rise in its Q1 revenue from its international...
-
UPDATE: Thermo Fisher Scientific Reports EPS of $0.92 vs. $0.88 Estimate; Revenues $2.72B vs. $2.65B Estimate (TMO)
Wednesday, April 27, 2011 - 8:53am | 23Thermo Fisher Scientific (NYSE: TMO) Reports EPS of $0.92 vs. $0.88 Estimate; Revenues $2.72B vs. $2.65B Estimate